OOIR: Observatory of International Research

Papers

(The TQCC of Liver International is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Issue Information	219
Methylprednisolone‐Induced Liver Injury: Insights From FAERS Analysis and Comparison With DILIN Findings	121
Integrating PNPLA3 into clinical risk prediction	119
Prognostic Role of Endoscopic Ultrasound Guided Direct Portal Pressure Gradient Measurement in Porto‐Sinusoidal Vascular Disorder	93
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct‐acting antivirals	88
HBV cure—The light at the end of the tunnel?	88
Fatty liver disease at the basis of cardiac remodelling and increased heart rate: Insights from the UK Biobank	81
Causal effect of lower birthweight on non‐alcoholic fatty liver disease and mediating roles of insulin resistance and metabolites	78
Is HCV elimination among persons living with HIV feasible? Data from the NoCo study in the setting of the ICONA cohort	70
Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta‐analysis	69
Importance of gender differences in body composition for liver transplantation and the ‘Sarco‐Model’ study	67
Five‐year outcomes in liver transplant patients receiving everolimus with or without a calcineurin inhibitor: Results from the CERTITUDE study	62
Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort	62
Navigating portal hypertension: Unlocking safe passage to healthy pregnancy in EHPVO	62
Is ageing a problematic hurdle to the efficacy of first‐line atezolizumab plus bevacizumab in hepatocellular carcinoma?	60
Inside Front Cover	60
Immunogenicity and safety of a third dose of anti‐SARS‐CoV‐2 BNT16b2 vaccine in liver transplant recipients	57
Changing epidemiological features of hepatocellular carcinoma: Taiwan's position	55
Letter to the Editor regarding “Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis”	55
Different methodologies of protein induced by vitamin K absence or antagonist II in patients without hepatocellular carcinoma	54
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	54
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib	53
High disease burden and healthcare resource usage in patients with acute porphyria—A population‐based analysis	53
Metformin synergistically enhances the antitumour activity of Lenvatinib in hepatocellular carcinoma by altering AKT‐FOXO3 signalling pathway	53
Issue Cover	52

A population‐based study of pyogenic liver abscess in Korea: Incidence, mortality and temporal trends during 2007‐2017	51
Interpreting elevated liver blood test results through a genetic lens: A genome‐wide association study	49
Think twice about IgG4‐related diseases before operating on hepatic masses	48
Is fresh frozen plasma transfusion associated with outcomes in acute variceal bleeding?	47
The integrated stress response‐related expression of CHOP due to mitochondrial toxicity is a warning sign for DILI liability	45
High prevalence of porto‐sinusoidal vascular disease in patients with constantly elevated gamma‐glutamyl transferase levels	45
Golexanolone improves fatigue, motor incoordination and gait and memory in rats with bile duct ligation	44
Perilipin 5 protects the mitochondrial oxidative functions and improves the alcoholic liver injury in mice	44
EpCam is required for maintaining the integrity of the biliary epithelium	43
Acute‐on‐chronic liver failure: Where do we stand?	43
An ultrasound image‐based deep multi‐scale texture network for liver fibrosis grading in patients with chronic HBV infection	42
Impact of major depression and antidepressant use on alcoholic and non‐alcoholic fatty liver disease: A population‐based study	42
Abnormal cholesterol metabolism underlies relative adrenal insufficiency in decompensated cirrhosis	41
Profiles of liver fibrosis evolution during long‐term tenofovir treatment in HIV‐positive patients coinfected with hepatitis B	41
Proprotein convertase subtilisin/kexin type 9 regulates the production of acute‐phase reactants from the liver	40
Bringing evidence to the MAFLD‐MASLD debate	39
Alcohol‐related hepatocellular carcinoma is a heterogenous condition: Lessons from a latent class analysis	38
Autoimmune hepatitis triggered by COVID‐19: A report of two cases	38
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis	38
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis	37
Impact of socio‐economic environment on incidence of primary liver cancer in France between 2006 and 2016	37
Prognosis of hospitalized patients with cirrhosis and acute kidney disease	36
Frequency of the PNPLA3 rs738409 polymorphism and other genetic loci for liver disease in a Guatemalan adult population	36
Reply: Herbal‐Induced Liver Injury Identification and Prevention	35
A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta‐Analysis	35
Ultra‐processed food is associated with features of metabolic syndrome and non‐alcoholic fatty liver disease	35
Correction to ‘Development and Validation of an Image Biomarker to Identify Metabolic Dysfunction Associated Steatohepatitis: MR‐MASH Score’	34
Association of Liver Disease and Chronic Pruritus: A Case–Control Study	34
Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs	34
Helicobacter pylori‐Associated Surrogate Markers of Intestinal Permeability, Bacterial Translocation and Gut Barrier Damage in Liver Cirrhosis	34
Low‐Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma	34
Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa	33
The Relationship Between TNF‐α Inhibitor Potency and HBV Reactivation in Patients With Rheumatic Disorders	33
Hepatocytic ballooning in non‐alcoholic steatohepatitis: Dilemmas and future directions	32
Liver Disease Complicating Familial Mediterranean Fever: A Study on 66 Patients Out of 533 Adult From the JIR Cohort	32
Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy	32
	32
Liver GPBAR1 Associates With Immune Dysfunction in Primary Sclerosing Cholangitis and Its Activation Attenuates Cholestasis in Abcb4−/− Mice	31
Case‐based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management	31
HCC advances in diagnosis and prognosis: Digital and Imaging	31
Axon guidance molecules in liver pathology: Journeys on a damaged passport	30
Issue Information	30
Gender differences of authors of major Hepatology society guidelines during the past 15 years	30
HLA matching between donors and recipients improves clinical liver transplant graft survival	30
Liver transplantation for autoimmune hepatitis: Pre‐transplant does not predict the early post‐transplant outcome	30
Autoimmune hepatitis or drug‐induced autoimmune hepatitis following Covid‐19 vaccination?	29
Letter to the editor regarding “Exploring the landscape of steatotic liver disease in the general US population”	29
Multiple arterial‐phase MRI with gadoxetic acid improves diagnosis of hepatocellular carcinoma ≤3.0 cm	29
Autoimmune hepatitis (AIH) following coronavirus (COVID‐19) vaccine—No longer exclusive to mRNA vaccine?	29
Patients hospitalized with alcohol‐related liver disease and prior bariatric surgery are more prone to develop acute‐on‐chronic liver failure	29

Bulevirtide for patients with compensated chronic hepatitis delta: A review	28
Characterization of lymphocyte‐rich hepatocellular carcinoma and the prognostic role of tertiary lymphoid structures	28
Hepatic cell junctions: Pulling a double‐duty	28
Global treatment rate and barriers to direct‐acting antiviral therapy: A systematic review and meta‐analysis of 146 studies and 1 760 352 hepatitis C virus patients	28
Research gaps and opportunities in autoimmune hepatitis—Results of the international autoimmune hepatitis group research workshop 2022	28
Inferior cure rate in pilot study of 4‐week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C	28
Extracellular vesicles in fatty liver disease and steatohepatitis: Role as biomarkers and therapeutic targets	28
Sodium–glucose linked transporter 2 inhibitors in liver cirrhosis: Beyond their antidiabetic use	28
Outcomes and management in paediatric autoimmune hepatitis presenting as acute liver failure: Individual patient data meta‐analysis	28
Brain metabolic and microstructural alterations associated with hepatitis C virus infection, autoimmune hepatitis and primary biliary cholangitis	28
Lenvatinib, sintilimab plus transarterial chemoembolization for advanced stage hepatocellular carcinoma: A phase II study	28
Response to letter from Skouloudi et al	28
Gastrointestinal cancers in lean individuals with non‐alcoholic fatty liver disease: A systematic review and meta‐analysis	27
An MMP‐degraded and cross‐linked fragment of type III collagen as a non‐invasive biomarker of hepatic fibrosis resolution	27
Hepatic Recompensation Before Systemic Therapy for Hepatocellular Carcinoma Yields Comparable Survival to Compensated Cirrhosis	26
Health‐related quality of life in patients with primary sclerosing cholangitis: A longitudinal population‐based cohort study	26
NSBBs, EBL or Combined Therapy for High‐Risk Varices: Systematic Review and Meta‐Analysis	26
Red meat intake, faecal microbiome, serum trimethylamine N‐oxide and hepatic steatosis among Chinese adults	26
¹⁶⁶Ho‐RadioEmbolizaTiOn Using personalized prediCtive dosimetry in patients with Hepatocellular carcinoma: A prospective, single‐centre study (RETOUCH)	25
Inhibition of MALT1 Protease Attenuates Hepatic Sinusoidal Obstruction Syndrome by Modulating NRF2/HO1 and NF‐κB Pathway	25
Enhancing the Understanding of Obesity and Liver Health: Addressing Lifestyle, Socio‐economic and Ethnic Disparities	25
Early virological response in six patients with hepatitis D virus infection and compensated cirrhosis treated with Bulevirtide in real‐life	25
Response to: Impact of GLP‐1RA on Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes	25
Microvesicle Tissue Factor Procoagulant Activity Is Elevated and Correlated With Disease Severity in Patients With Cirrhosis	25
Nonalcoholic fatty liver disease without overlapping metabolic‐associated fatty liver disease and the risk of incident type 2 diabetes	24
Hepatitis C screening during SARS‐CoV‐2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno	24
Prognostic Implications of Cardiac Geometry in Cirrhosis: Findings From a Large Cohort	24
Author's reply: Plasma corticosteroid‐binding globulin levels in cirrhosis	24
Practical recommendations for biochemical and genetic diagnosis of the porphyrias	24
Enhanced muscle function in cause‐specific mortality among patients with NAFLD‐related sarcopenia	24
Third dose of mRNA COVID‐19 vaccine and response: Correspondence	24
Issue Information	24
Alcohol‐related liver disease phenotype impacts survival after an acute variceal bleeding episode	23
Predictors of mid‐term survival after liver transplantation in patients with NAFLD cirrhosis	23
3‐Mercaptopyruvate sulfurtransferase in hepatocellular carcinoma: Is it an authentic clinical prognostic predictor?	23
Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype?	23
Determining reinfection rates by hepatitis C testing interval among key populations: A systematic review and meta‐analysis	23
Trends in prevalence of probable fibrotic non‐alcoholic steatohepatitis in the United States, 1999–2016	22
Immune checkpoint inhibitors in malignancies after liver transplantation: Better safe or sorry?	22
Extrahepatic autoimmune diseases do not increase the mortality of autoimmune hepatitis	22
NAFLD and NASH are obesity‐independent risk factors in COVID‐19: Matched real‐world results from the large PINC AI™ Healthcare Database	21
Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series	21
Issue Information	21
The changing epidemiology of liver diseases in Asia	21
Primary sclerosing cholangitis with moderately elevated serum‐IgG4 – characterization and outcome of a distinct variant phenotype	21
Is it time to get rid of the biopsy mandate in adults with suspected autoimmune hepatitis? Lessons from the COVID‐19 pandemic	21
Issue Information	21
Regulation of the macrophage‐hepatic stellate cell interaction by targeting macrophage peroxisome proliferator‐activated receptor gamma to prevent non‐alcoholic steatohepatitis progression in mice	21
A genetic variant in toll‐like receptor 5 is linked to chemokine levels and hepatocellular carcinoma in steatohepatitis	21
Hepatic triglyceride content is intricately associated with numerous metabolites and biochemical pathways	21
Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation	21
Practice patterns and outcomes associated with intravenous albumin in patients with cirrhosis and acute kidney injury	21
Issue Information	21
The Global Burden of Cirrhosis and Other Chronic Liver Diseases in 2021	20
Estimated glomerular filtration rate by formulas in patients with cirrhosis: An unreliable procedure	20
How best to combine liver transplantation and bariatric surgery?—Results from a global, web‐based survey	20
Bcl‐x_L as prognostic marker and potential therapeutic target in cholangiocarcinoma	20
Apolipoprotein A‐1 protected hepatic ischaemia–reperfusion injury through suppressing macrophage pyroptosis via TLR4–NF‐κB pathway	20
An ultrasound multiparametric method to quantify liver fat using magnetic resonance as standard reference	20
Treatment and the prognosis of hepatocellular carcinoma in Asia	20
Unmet needs in autoimmune hepatitis: Results of the prospective multicentre European Reference Network Registry (R‐LIVER)	20
Quality Measures to Enhance the Management and Treatment of Primary Biliary Cholangitis: A Delphi Consensus Study	20
	19
Issue Information	19
Issue Information	19
Comparison of primary liver cancer mortality estimates from World Health Organization, global burden disease and global cancer observatory	19
Global trends and the impact of chronic hepatitis B and C on disability‐adjusted life years	19
Real‐world evidence in hepatocellular carcinoma	19
On‐treatment gamma‐glutamyl transferase predicts the development of hepatocellular carcinoma in chronic hepatitis B patients	19
Issue Information	19
Outcome of Liver Retransplantation in Patients With Primary Sclerosing Cholangitis	19
Refining the Safety Perspective of Bulevirtide in Chronic Hepatitis Delta Management	18
The utility of hierarchical genetic testing in paediatric liver disease	18
Association of thyroid function with non‐alcoholic fatty liver disease in recent‐onset diabetes	18
Management, outcomes and survival of an Australian IgG4‐SC cohort: The MOSAIC study	18
Reply to: Blood urea better than creatinine in prognosticating post‐TIPS outcomes: Hope or hype?	18
Identification of Distinguishing Features of Drug‐Induced Liver Injury and Liver Injury Associated With Sepsis	18
Reply to the letter “Anti‐HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B”	18
Holistic management of hepatocellular carcinoma: The hepatologist's comprehensive playbook	18
Risk factors for bleeding hepatocellular adenoma in a United States cohort	18

Expanding the donor pool: Kidney transplantation from serum HBV DNA or HBeAg‐positive donors to HBsAg‐negative recipients	18
Oxidised Apolipoprotein Peptidome Characterises Metabolic Dysfunction‐Associated Steatotic Liver Disease	18
Quality‐of‐life scores improve after 96 weeks of PEG‐IFNa‐2a treatment of hepatitis D: An analysis of the HIDIT‐II trial	18
Future anti‐HDV treatment strategies, including those aimed at HBV functional cure	18
Alcohol‐related hepatitis admissions increased 50% in the first months of the COVID‐19 pandemic in the USA	18
Management of NAFLD patients with advanced fibrosis	17
FBXO31 sensitizes cancer stem cells‐like cells to cisplatin by promoting ferroptosis and facilitating proteasomal degradation of GPX4 in cholangiocarcinoma	17
Pilot hepatitis C micro‐elimination strategy in Pakistani migrants in Catalonia through a community intervention	17
Treatment patterns for hepatocellular carcinoma in patients with Child–Pugh class B and their impact on survival: A Korean nationwide registry study	17
Acute Transient Aminotransferase Elevation is Common With Intrathecal Methotrexate, but Liver Injury is Infrequent	17
Collagen proportionate area correlates with histological stage and predicts clinical events in primary sclerosing cholangitis	17
Bacterial Infections in Severe Alcohol‐Associated Hepatitis: Methodological Considerations	17
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis	17
Escherichia coli‐derived outer‐membrane vesicles induce immune activation and progression of cirrhosis in mice and humans	17
Follow‐up post‐HCV virological response to DAA in advanced chronic liver disease	17
French guidelines on TIPS: Indications and modalities	17
Protective role of cGAS in NASH is related to the maintenance of intestinal homeostasis	17
Altered ethanol metabolism and increased oxidative stress enhance alcohol‐associated liver injury in farnesoid X receptor‐deficient mice	17
Impact of GLP‐1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes	17
Issue Information	16
Adipose tissue dysfunction and visceral fat are associated with hepatic insulin resistance and severity of NASH even in lean individuals	16
Carvedilol as the new non‐selective beta‐blocker of choice in patients with cirrhosis and portal hypertension	16
Issue Information	16
MASLD and MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint	16
	16
Ketogenic Diet and Hepatic Ischaemia–Reperfusion Injury: Aggravation or Mitigation?	16
Hepatocellular carcinoma: The virus or the liver?	16
Issue Information	16
Issue Information	15
Recipient‐Donor Sex Constellation in Liver Transplantation for Hepatocellular Carcinoma: An ELTR Study — Author Reply	15
Acute alcohol‐associated hepatitis: Latest findings in non‐invasive biomarkers and treatment	15
Inside Front Cover	15
Global burden of acute hepatitis E between 1990 and 2019 and projections until 2030	15
	15
Inhibition of IRE‐1α Alleviates Pyroptosis and Metabolic Dysfunction‐Associated Steatohepatitis by Suppressing Gasdermin D	15
Preoperative magnetic resonance imaging‐based prognostic model for mass‐forming intrahepatic cholangiocarcinoma	15
Transjugular intrahepatic portosystemic shunt for portal hypertension: 30 years experience from China	15
Molecular mechanism of albumin in suppressing invasion and metastasis of hepatocellular carcinoma	15
Front Cover	15
	15
The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection	15
Stenting of ductus venosus as a palliation for portal hypertension because of neonatal cirrhosis	15
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma	15
Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease	14
Epidemiology and surveillance of autoimmune hepatitis in Asia	14
Mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome	14
PRO‐C3, liver fibrosis and CKD: The plot thickens	14
Deficient chaperone‐mediated autophagy in macrophage aggravates inflammation of nonalcoholic steatohepatitis by targeting Nup85	14
Response Letter to: Zebrafish: An emerging and expedient model for liver studies?	14
Protective effects of statins on the incidence of NAFLD–related decompensated cirrhosis in T2DM	14
MASLD And MASH Risk: Does Losing Obesity Reverse the Metabolic Footprint?	14
Trajectories of glycaemic traits exhibit sex‐specific associations with hepatic iron and fat content: Results from the KORA‐MRI study	14
Impact of sarcopenia on postoperative outcomes after hepatectomy in older patients with intrahepatic cholangiocarcinoma: A multicentre cohort study	14
The price tag of a potential cure for chronic hepatitis B infection: A cost threshold analysis for USA, China and Australia	14
Histological characterization of liver involvement in systemic mastocytosis	14
Sweating it out: How physical activity can combat high genetic risk for nonalcoholic fatty liver disease	14
Novel insights into metabolic‐associated steatotic liver disease preclinical models	14
Optimizing large language models in digestive disease: strategies and challenges to improve clinical outcomes	14
Response to: Letter to the Editor “Child‐Turcotte‐Pugh score as a model for organ allocation in liver transplantation, perhaps old is still gold”	14
Autophagy in liver regeneration: Unravelling the endothelial cell's role and therapeutic prospects	14
NR1H4 rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease	14
The prognostic role of tumour progression and liver function at progression under immunotherapy for hepatocellular carcinoma	14
Overcoming the challenges of eliminating viral hepatitis in low‐ and middle‐income countries	14
Can alcohol control policies reduce cirrhosis mortality? An interrupted time‐series analysis in Lithuania	13
The immuno‐therapeutic potential of miR‐2392 in patients with hepatocellular carcinoma	13
Response to comments on ‘Changing landscape of alcohol‐associated liver disease in younger individuals, women and ethnic minorities’	13
Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump	13
Excessive fatty acids activate PRMT5/MDM2/Drosha pathway to regulate miRNA biogenesis and lipid metabolism	13
Development of a simple dynamic algorithm for individualized hepatocellular carcinoma risk‐based surveillance using pre‐ and post‐treatment general evaluation score	13
Zebrafish: An emerging and expedient model for liver studies?	13
Usefulness of controlled attenuation parameter in monitoring clinically relevant decline of hepatic steatosis for non‐alcoholic fatty liver disease	13
	13
Efficacy and safety of percutaneous cryoablation for elderly patients with small hepatocellular carcinoma: A prospective multicenter study	13
Leflunomide‐induced liver injury: Differences in characteristics and outcomes in Indian and US registries	13
Letter regarding ‘mitochondrial amidoxime‐reducing component 1 p.Ala165Thr increases protein degradation mediated by the proteasome’	13
MAIT cells ameliorate liver fibrosis by enhancing the cytotoxicity of NK cells in cholestatic murine models	13
Alcohol consumption and liver phenotype of individuals with alpha‐1 antitrypsin deficiency	13
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment‐naïve chronic hepatitis B	13
Beneficial effects of hepatic cyclooxygenase‐2 expression against cholestatic injury after common bile duct ligation in mice	13
Material deprivation is associated with liver stiffness and liver‐related outcomes in people with HIV	13
Nuclear translocation of YAP drives BMI‐associated hepatocarcinogenesis in hepatitis B virus infection	13
Hepatic Steatosis and Fibrosis, Cardiorespiratory Fitness, and Metabolic Mediators in the Community	13
Management of alcoholic hepatitis: A clinical perspective	13
PNPLA3 variation and kidney disease	13
The importance of prospective drug‐induced liver injury registries	13
Nucleos(t)ide analogue therapy: The role of tenofovir alafenamide	13
Issue Cover	13
Development of pre and post‐operative nomograms to predict individual survival for ideal liver resection candidates with hepatocellular carcinoma	13
Clinical characteristics and prognosis of early diagnosed Wilson's disease: A large cohort study	13
Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population‐based study	13
Hepatitis Delta: Ready for primetime?	13
Outcomes after liver transplantation using deceased after circulatory death donors: A comparison of outcomes in the UK and the US	13
Characteristics and outcome of anti‐hepatitis D virus positive patients with hepatocellular carcinoma	13
A Transformer‐Based microvascular invasion classifier enhances prognostic stratification in HCC following radiofrequency ablation	13
Response Letter to: Association of thyroid function with nonalcoholic fatty liver disease in recent‐onset diabetes	13